Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJM347 in Healthy Male Caucasian and Japanese Subjects in the Fasted and Fed State

Inclusion Criteria: Main Inclusion Criteria for all participants: * Participants will be male * Participants will be in good health Main Inclusion Criteria for Japanese participants: * Be ≥20 to ≤45 years of age * Have body mass index (BMI) ≥18.5 to ≤25.0 kilograms per meters squared (kg/m\^2) * Be Japanese Main Inclusion Criteria for Caucasian participants: * Be ≥18 to ≤45 years of age * Have a BMI ≥18.5 to ≤30.0 kg/m\^2 * Be Caucasian Exclusion Criteria: Main Exclusion Criteria for all participants: Participants will be excluded from the study if they satisfy any of the following criteria at the Screening visit, unless otherwise stated. * Participants who have donated or lost ≥200 milliliters (mL) blood within 1 month or ≥400 mL within 3 months prior to Check-in * Participants who have an abnormality in heart rate, blood pressure, temperature, or respiration rate at Screening * Participants who have: * a positive urine drugs of abuse screen; * a positive alcohol breath test * Participants who have an abnormality in the 12-lead electrocardiogram (ECG) at Screening * Participants who are still participating in another clinical study (eg, attending follow-up visits) or who have participated in a clinical study involving administration of an investigational drug (new chemical entity) in the past 3 months prior to first dose administration * Participants who have a significant history of drug allergy, as determined by the Investigator * Participants who have any clinically significant abnormal physical examination finding * Participants who: * are carriers of the hepatitis B surface antigen (HBsAg); * are carriers of the hepatitis C antibody; * have a positive result for the test for human immunodeficiency virus (HIV) antibodies * Participants who, in the opinion of the Investigator, should not participate in this study